EMA to review axitinib for RCC

EMA accepted for review an MAA from Pfizer Inc. (NYSE:PFE) for axitinib to treat advanced renal cell carcinoma after failure of prior systemic treatment. Axitinib is an inhibitor of VEGF receptors 1, ...